Skip to main content

Table 2 Significantly altered targets in analyzed cohorts

From: Expression of NALPs in adipose and the fibrotic progression of non-alcoholic fatty liver disease in obese subjects

  Pericellular fibrosis presence (N = 20) Pericellular fibrosis absence (N = 25) P value
AST (U/L) 34.75 ± 25.06 22.62 ± 9.19 0.023
Males 50.0% 19.0% 0.036
Females 35.7% 25% NS
Advanced fibrosis presence (Score ≥ 3) 60% 9.5% 0.0006
NALP4 mRNA 0.18 ± 0.20 1.12 ± 2.53 0.019
IL1B mRNA 6.17 ± 12.05 14.96 ± 18.21 0.003
  Portal fibrosis presence (N = 34) Portal fibrosis absence (N = 11) P value
Advanced fibrosis presence (Score ≥ 3) 45.2% 0 0.008
NASH 58.1% 20% 0.03
NALP6 mRNA 0.86 ± 0.93 0.38 ± 0.38 0.028
IL-18 (pg/mL) 390.95 pg/mL ± 176.84 246.08 pg/mL ± 103.10 0.022
  NASH (N = 20) Non-NASH NAFLD (N = 25) P value
Gender (Females) 50% 81% < 0.036
Portal Fibrosis (presence) 1.35 ± 0.67 0.71 ± 0.64 < 0.005
Pericellular Fibrosis (presence) 1.45 ± 0.60 0.05 ± 0.22 < 0.001
Advanced fibrosis (Score ≥ 3) 60% 9.5% < 0.0006
Degree of lobular inflammation 2.55 ± 1.61 1.52 ± 0.98 < 0.02
AST (U/L) 35.70 ± 24.79 21.71 ± 8.52 < 0.004
NALP 4 mRNA 0.16 ± 0.19 1.14 ± 2.53 < 0.002
NALP 5 mRNA 0.14 ± 0.12 1.24 ± 2.58 < 0.02
NALP 7 mRNA 0.14 ± 0.12 1.09 ± 2.54 < 0.03
NALP 8 mRNA 0.14 ± 0.12 1.09 ± 2.54 < 0.03
NALP 9 mRNA 0.14 ± 0.12 1.25 ± 2.70 < 0.03
NALP 10 mRNA 0.14 ± 0.12 1.09 ± 2.54 < 0.03
NALP 11 mRNA 0.14 ± 0.12 1.09 ± 2.54 < 0.02
NALP 13 mRNA 0.14 ± 0.12 1.09 ± 2.54 < 0.03
IL-1B mRNA 8.71 ± 15.45 12.66 ± 16.68 < 0.02